Inflammation-Reducing Drug Minocycline Shows No Benefit For Dry Age-Related Macular Degeneration in NIH Trial
March 20, 2024 -- The drug minocycline, an antibiotic that also decreases inflammation, failed to slow vision loss or expansion of geographic atrophy in people with dry age-related macular degeneration (AMD), according to a phase II clinical study... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 20, 2024 Category: Pharmaceuticals Source Type: clinical trials
Experimental Gene Therapy for Giant Axonal Neuropathy Shows Promise in NIH Clinical Trial
March 20, 2024 -- An investigational gene therapy for a rare neurodegenerative disease that begins in early childhood, known as giant axonal neuropathy (GAN), was well tolerated and showed signs of therapeutic benefit in a clinical... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 20, 2024 Category: Pharmaceuticals Source Type: clinical trials
Bill & Melinda Gates Medical Research Institute Initiates Phase 3 Clinical Trial of Tuberculosis Vaccine Candidate
CAMBRIDGE, Mass., March 19, 2024. The Bill& Melinda Gates Medical Research Institute (Gates MRI) today announced that a Phase 3 clinical trial to assess the efficacy of the M72/AS01E tuberculosis (TB) vaccine candidate is now underway, with... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 20, 2024 Category: Pharmaceuticals Source Type: clinical trials
Merck Announces Positive Data on V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults
RAHWAY, N.J.--(BUSINESS WIRE) March 19, 2024 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive data from multiple Phase 3 studies evaluating V116, the company’s investigational,... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 19, 2024 Category: Pharmaceuticals Source Type: clinical trials
Positive Results from Phase 3 BouNDless Trial of Investigational ND0612 in People with Parkinson's Disease Experiencing Motor Fluctuation
JERSEY CITY, N.J., March 18, 2024. Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the publication of results in The Lancet Neurology from the pivotal, Phase 3 BouNDless trial (NCT04006210) evaluating the efficacy, safety and... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 18, 2024 Category: Pharmaceuticals Source Type: clinical trials
Repurposed Drug Fenoprofen Shows Promise Against Endometriosis-Related Pain in Animal Model
March 18, 2024 -- Fenoprofen, a nonsteroidal anti-inflammatory drug (NSAID), successfully alleviated pain and inflammation in a rodent model of endometriosis, according to researchers funded by the National Institutes of Health (NIH). They chose the... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 18, 2024 Category: Pharmaceuticals Source Type: clinical trials
myTomorrows Partners with The ALS Association to Support ALS Patients in Accessing Clinical Trials
NEW YORK, March 14, 2024. myTomorrows today announced a new partnership with the ALS Association, the U.S.-based nonprofit organization fighting ALS on every front.
myTomorrows is a global health technology company shaping the future landscape of... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 15, 2024 Category: Pharmaceuticals Source Type: clinical trials
Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS
FOSTER CITY, Calif.--(BUSINESS WIRE) March 14, 2024 -- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies,... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 14, 2024 Category: Pharmaceuticals Source Type: clinical trials
Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes
LEXINGTON, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 14, 2024 Category: Pharmaceuticals Source Type: clinical trials
Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder
TORONTO--(BUSINESS WIRE) March 13, 2024 --Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the“Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 13, 2024 Category: Pharmaceuticals Source Type: clinical trials
PureTech Receives Orphan Drug Designation for LYT-200 in Acute Myeloid Leukemia
13 March 2024 -- PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ( " PureTech " or the " Company " ), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that the U.S. Food and Drug... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 13, 2024 Category: Pharmaceuticals Source Type: clinical trials
Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)
LONDON--(BUSINESS WIRE) March 13, 2024 -- Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the“Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 13, 2024 Category: Pharmaceuticals Source Type: clinical trials
Ionis Announces Positive Results from Phase 2 Study of ION224, an Investigational Medicine Demonstrating Clinical Efficacy in the Treatment of NASH/MASH
CARLSBAD, Calif., March 13, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced positive results from a Phase 2 study of ION224, an investigational DGAT2 antisense inhibitor in development for the treatment of metabolic... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 13, 2024 Category: Pharmaceuticals Source Type: clinical trials
Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia
OSAKA, Japan, and CAMBRIDGE, Massachusetts, March 13, 2024– Takeda (TSE:4502/NYSE:TAK) today announced positive topline results from a Phase 2, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability and... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 13, 2024 Category: Pharmaceuticals Source Type: clinical trials
Delta-8-THC Use Reported by 11% of 12th Graders in 2023
March 12, 2024 -- Use of the psychoactive cannabis product is higher in states without existing delta-8 regulations or cannabis legalization, NIH-funded study finds.
Approximately 11% of 12th-grade students across the United States reported... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 12, 2024 Category: Pharmaceuticals Source Type: clinical trials
